drugset / Trial / NCT04074096
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
Phase 2
Active not recruiting
10 enrolled
UNICANCER
European Association of Dermato Oncology · collabMerck Sharp & Dohme LLC · collabPierre Fabre Medicament · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of binimetinib + encorafenib + pembrolizumab in the treatment of BRAFⱽ⁶⁰⁰ mutation-positive melanoma with brain metastases (MBM).
Timeline
- Start
- 2022-09-05
- Primary completion
- 2026-05-07
- Completion
- 2027-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | 45 mg | Oral |
| Subject | Encorafenib | Small molecule | 450 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |